Your browser doesn't support javascript.
loading
Efficacy and Safety of Concurrent Chemoradiotherapy of Paclitaxel and Carboplatin as Adjuvant Therapy after Primary Surgery in High-risk Cervical Cancer / 대한산부인과학회잡지
Korean Journal of Obstetrics and Gynecology ; : 917-923, 2004.
Article in Korean | WPRIM | ID: wpr-16638
ABSTRACT

OBJECTIVE:

To evaluate the efficacy and safety of concurrent chemotherapy of paclitaxel and carboplatin with standard pelvic radiotherapy as adjuvant therapy after primary surgery in high-risk cervical cancer.

METHODS:

Twenty-eight patients with FIGO stage IB1-IIB cervical cancer who received adjuvant concurrent chemoradiotherapy with paclitaxel and carboplatin from February 2000 to November 2001 were analyzed retrospectively in this study. Adjuvant chemoradiotherapy was done if there were lymph node involvement or at least 2 positive findings among following risk factors; lymphovascular space invasion, full- thickness involvement of cervix and tumor size larger than 4 cm in diameter. Two cycles of paclitaxel 135 mg/m2, followed by carboplatin with AUC of 4.5 were administered intravenously with an interval of at least 4 weeks. The radiotherapy was initiated concurrently at the first day of chemotherapy. The therapeutic results were evaluated by pelvic examination, Pap smear, SCCA (Squamous cell carcinoma antigen) and computed tomography (CT). The toxicities of the treatment were evaluated and graded by NCI-CTC version 2.0.

RESULTS:

Total 56 cycles of paclitaxel/carboplatin chemotherapy with concomitant pelvic radiotherapy was delivered. None of the patients had a progressive or recurrent disease during the follow-up period ranging from 6 to 33 months (median 12.5 months). Neutropenia was the most common and concerned toxicity. Fifteen cases of grade 3 and 4 neutropenia (26.8%) were observed. Non-hematologic toxicities were mild and mainly related to neurologic or gastrointestinal symptoms. Eight cases of grade 1 and 2 neurotoxicity were observed (14.3%).

CONCLUSION:

The adjuvant chemoradiotherapy with paclitaxel and carboplatin seems to be effective and well-tolerated for the treatment of high risk group cervical cancer after primary surgical therapy. But a large randomized study with longer duration of follow-up is needed to justify this conclusion.
Subject(s)

Full text: Available Index: WPRIM (Western Pacific) Main subject: Radiotherapy / Uterine Cervical Neoplasms / Cervix Uteri / Retrospective Studies / Risk Factors / Follow-Up Studies / Carboplatin / Paclitaxel / Area Under Curve / Drug Therapy Type of study: Etiology study / Observational study / Prognostic study / Risk factors Limits: Female / Humans Language: Korean Journal: Korean Journal of Obstetrics and Gynecology Year: 2004 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Radiotherapy / Uterine Cervical Neoplasms / Cervix Uteri / Retrospective Studies / Risk Factors / Follow-Up Studies / Carboplatin / Paclitaxel / Area Under Curve / Drug Therapy Type of study: Etiology study / Observational study / Prognostic study / Risk factors Limits: Female / Humans Language: Korean Journal: Korean Journal of Obstetrics and Gynecology Year: 2004 Type: Article